1. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
- Author
-
Hoff, Nicole A, Bratcher, Anna, Kelly, J Daniel, Musene, Kamy, Kompany, Jean Paul, Kabamba, Michel, Mbala-Kingebeni, Placide, Dighero-Kemp, Bonnie, Kocher, Gregory, Elliott, Elizabeth, Reilly, Cavan, Halbrook, Megan, Kebela, Benoit Ilunga, Gadoth, Adva, Mwamba, Guillaume Ngoie, Tambu, Merly, McIlwain, David R, Mukadi, Patrick, Hensley, Lisa E, Ahuka-Mundeke, Steve, Rutherford, George W, Muyembe-Tamfum, Jean Jacques, and Rimoin, Anne W
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Infectious Diseases ,Immunization ,Emerging Infectious Diseases ,Biodefense ,Vaccine Related ,Prevention ,Prevention of disease and conditions ,and promotion of well-being ,3.4 Vaccines ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Antibodies ,Viral ,Child ,Democratic Republic of the Congo ,Disease Outbreaks ,Ebola Vaccines ,Ebolavirus ,Female ,Glycoproteins ,Hemorrhagic Fever ,Ebola ,Humans ,Immunogenicity ,Vaccine ,Male ,Middle Aged ,Seroepidemiologic Studies ,Vaccination ,Viral Envelope Proteins ,Young Adult ,Ebola virus disease ,Ebola vaccine ,rVSV Delta G-ZEBOV-GP ,immunogenicity ,rVSVΔG-ZEBOV-GP - Abstract
Despite more than 300,000 rVSVΔG-ZEBOV-glycoprotein (GP) vaccine doses having been administered during Ebola virus disease (EVD) outbreaks in the Democratic Republic of the Congo (DRC) between 2018 and 2020, seroepidemiologic studies of vaccinated Congolese populations are lacking. This study examines the antibody response at 21 d and 6 mo postvaccination after single-dose rVSVΔG-ZEBOV-GP vaccination among EVD-exposed and potentially exposed populations in the DRC. We conducted a longitudinal cohort study of 608 rVSVΔG-ZEBOV-GP-vaccinated individuals during an EVD outbreak in North Kivu Province, DRC. Participants provided questionnaires and blood samples at three study visits (day 0, visit 1; day 21, visit 2; and month 6, visit 3). Anti-GP immunoglobulin G (IgG) antibody titers were measured in serum by the Filovirus Animal Nonclinical Group anti-Ebola virus GP IgG enzyme-linked immunosorbent assay. Antibody response was defined as an antibody titer that had increased fourfold from visit 1 to visit 2 and was above four times the lower limit of quantification at visit 2; antibody persistence was defined as a similar increase from visit 1 to visit 3. We then examined demographics for associations with follow-up antibody titers using generalized linear mixed models. A majority of the sample, 87.2%, had an antibody response at visit 2, and 95.6% demonstrated antibody persistence at visit 3. Being female and of young age was predictive of a higher antibody titer postvaccination. Antibody response and persistence after Ebola vaccination was robust in this cohort, confirming findings from outside of the DRC.
- Published
- 2022